Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$249.00
-2.00 (-0.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $175.0M · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$12.5B
P/E
13.5x
↓EV/EBITDA
7.5x
↓ROE
10.8%
↑Gross Margin
54.4%
↑Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.3%
FCF CAGR
—
FCF margin
8.0%
FCF / Net income
0.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.40B · net income $923.0M · FCF $510.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.40B | $6.40B | $6.29B | $6.12B | $5.04B |
| Net Income | $923.0M | $923.0M | $898.0M | $-3.61B | $-4.89B |
| EBITDA | $1.23B | $1.23B | $829.0M | $-2.85B | $-4.12B |
| EPS | 18.38 | 18.38 | 17.90 | -76.25 | -112.26 |
| Gross Margin | 54.4% | 54.4% | 58.3% | 42.1% | 21.4% |
| Operating Margin | 7.2% | 7.2% | 10.0% | -16.4% | -61.1% |
| Net Margin | 14.4% | 14.4% | 14.3% | -59.0% | -97.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | 0.28 | 0.48 | 0.47 |
| Current Ratio | 2.65 | 2.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $510.0M | $510.0M | $175.0M | $-421.0M | $-2.08B |
| Returns | |||||
| ROE | 10.8% | 10.8% | 11.3% | -53.6% | -60.9% |
| Valuation | |||||
| P/E | 13.54 | 13.54 | 18.49 | — | — |
| EV/EBITDA | 7.51 | 7.51 | 17.24 | — | — |
| P/B | 1.47 | 1.47 | 2.09 | 2.06 | 2.00 |
| Growth & Yield | |||||
| Revenue Growth | 1.7% | 1.7% | 2.8% | 21.4% | — |
| EPS Growth | 2.7% | 2.7% | 123.5% | 32.1% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
6.3%
EPS terminal req.
$22.09
Spread vs growth
-3.6%
5Y implied EPS CAGR
7.8%
EPS terminal req.
$26.73
Spread vs growth
-5.1%
10Y implied EPS CAGR
8.9%
EPS terminal req.
$43.06
Spread vs growth
-6.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.8%
Start / end P/E
14.1x → 13.8x
EPS bridge
17.90 → 18.38
Residual
-0.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.